CX3CL1通过JAK/STAT3轴促进ESCC中T细胞耗竭的机制研究

Despite the transformative impact of T cell therapy on hematologic cancers, its efficacy in solid tumors such as esophageal squamous cell carcinoma (ESCC) is hampered by T cell exhaustion and poor tumor infiltration. By establishing an immunocompetent ESCC mouse model and conducting single-cell RNA sequencing (scRNA-seq), we have generated a dynamic single-cell atlas of tumor evolution across four distinct phases: immune surveillance, immune equilibrium, immune suppression, and immune escape. We found that CX3CL1 is highly enriched in the immune suppression stage and associated with T cell exhaustion. Further GO analysis demonstrated that CX3CL1⁺ tumor cells activate the JAK/STAT3 signaling pathway. Both in vitro co-culture systems and in vivo studies showed that treatment with CX3CL1-neutralizing antibodies and JAK inhibitors effectively enhances T cell cytotoxicity and promotes tumor cell apoptosis. Combined therapy with PD-1 inhibitors and CX3CL1-neutralizing antibodies/JAK inhibitors significantly suppressed the growth of subcutaneous ESCC tumors in mice. Our findings indicate that CX3CL1 is a potential therapeutic target in ESCC, and targeting the CX3CL1/JAK/STAT3 axis in combination with immune checkpoint inhibitors may confer potential benefits to ESCC patients.